These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 38730087)
21. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation. Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978 [TBL] [Abstract][Full Text] [Related]
22. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
23. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Natarajan A; Habte F; Gambhir SS Bioconjug Chem; 2012 Jun; 23(6):1221-9. PubMed ID: 22621257 [TBL] [Abstract][Full Text] [Related]
24. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891 [TBL] [Abstract][Full Text] [Related]
25. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258 [TBL] [Abstract][Full Text] [Related]
26. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091 [TBL] [Abstract][Full Text] [Related]
27. Development of a Specifically Labeled Zheng M; Liu Q; Zhang H; Wang Y; Zhang K; Mu H; Fu F; Zhang X; Wang Y; Miao L Mol Pharm; 2024 Oct; 21(10):5205-5216. PubMed ID: 39322604 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of Chelator-to-Antibody Ratio on Development of Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961 [No Abstract] [Full Text] [Related]
29. Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190 [TBL] [Abstract][Full Text] [Related]
30. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418 [TBL] [Abstract][Full Text] [Related]
31. Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer. Parent EE; Gleba JJ; Knight JA; Kenderian SJ; Copland JA; Cai H Mol Imaging Biol; 2024 Oct; 26(5):847-857. PubMed ID: 39174789 [TBL] [Abstract][Full Text] [Related]
32. Development of [ Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372 [TBL] [Abstract][Full Text] [Related]
33. In Vitro and In Vivo Characterization of Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126 [No Abstract] [Full Text] [Related]
35. Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with Burvenich IJG; Wichmann CW; McDonald AF; Guo N; Rigopoulos A; Huynh N; Vail M; Allen S; O'Keefe GJ; Scott FE; Soikes R; Angelides S; Roemeling RV; Scott AM Eur J Nucl Med Mol Imaging; 2024 Nov; 51(13):3863-3873. PubMed ID: 39060374 [TBL] [Abstract][Full Text] [Related]
36. ImmunoPET imaging of tissue factor expression in pancreatic cancer with Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831 [TBL] [Abstract][Full Text] [Related]
37. Molecular imaging of T cell co-regulator factor B7-H3 with Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047 [TBL] [Abstract][Full Text] [Related]
38. MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides. Jacobson O; Zhu L; Niu G; Weiss ID; Szajek LP; Ma Y; Sun X; Yan Y; Kiesewetter DO; Liu S; Chen X Mol Imaging Biol; 2011 Dec; 13(6):1224-33. PubMed ID: 21161690 [TBL] [Abstract][Full Text] [Related]
39. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours. Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614 [TBL] [Abstract][Full Text] [Related]
40. Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy. Magro N; Oteo M; Romero E; Ibáñez-Moragues M; Lujan VM; Martínez L; Vela O; López-Melero ME; Arroyo AG; Garaulet G; Martínez-Torrecuadrada JL; Mulero F; Morcillo MA Nucl Med Biol; 2024; 136-137():108930. PubMed ID: 38833768 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]